EP3971208A4 - Anticorps dirigé contre la claudine 18a2 et son utilisation - Google Patents
Anticorps dirigé contre la claudine 18a2 et son utilisation Download PDFInfo
- Publication number
- EP3971208A4 EP3971208A4 EP20805122.7A EP20805122A EP3971208A4 EP 3971208 A4 EP3971208 A4 EP 3971208A4 EP 20805122 A EP20805122 A EP 20805122A EP 3971208 A4 EP3971208 A4 EP 3971208A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- claudin
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910406762 | 2019-05-16 | ||
| PCT/CN2020/090427 WO2020228806A1 (fr) | 2019-05-16 | 2020-05-15 | Anticorps dirigé contre la claudine 18a2 et son utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3971208A1 EP3971208A1 (fr) | 2022-03-23 |
| EP3971208A4 true EP3971208A4 (fr) | 2022-11-30 |
Family
ID=73288945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20805122.7A Pending EP3971208A4 (fr) | 2019-05-16 | 2020-05-15 | Anticorps dirigé contre la claudine 18a2 et son utilisation |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12415853B2 (fr) |
| EP (1) | EP3971208A4 (fr) |
| JP (1) | JP7407841B2 (fr) |
| KR (1) | KR20220024010A (fr) |
| CN (1) | CN113825771B (fr) |
| AU (1) | AU2020273695B2 (fr) |
| BR (1) | BR112021023024A2 (fr) |
| CA (1) | CA3138414A1 (fr) |
| WO (1) | WO2020228806A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022100590A1 (fr) * | 2020-11-10 | 2022-05-19 | 齐鲁制药有限公司 | Anticorps humanisé enrichi en adcc pour claudin 18a2 et application associée |
| EP4245317A4 (fr) * | 2020-11-10 | 2024-11-06 | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. | Anticorps bispécifique pour claudin 18a2 et cd3 et application d'un anticorps bispécifique |
| CN114634566B (zh) * | 2020-12-16 | 2023-09-19 | 广州百暨基因科技有限公司 | 一种抗Claudin18_2的抗原结合片段、抗体及其应用 |
| EP4273167A4 (fr) * | 2020-12-30 | 2025-03-26 | Bio-Thera Solutions, Ltd. | Anticorps anti-cldn18.2, son procédé de préparation et son utilisation |
| CN114805571B (zh) * | 2021-01-28 | 2023-08-25 | 广西鹭港生物医药科技有限公司 | 抗cldn18.2抗体及其应用 |
| CN113416260B (zh) * | 2021-04-14 | 2022-02-01 | 南京凯地医疗技术有限公司 | 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用 |
| EP4335873A4 (fr) * | 2021-05-08 | 2025-03-19 | RemeGen Co., Ltd. | Anticorps anti-claudine 18.2 et conjugué anticorps-médicament de celui-ci |
| AU2022287071A1 (en) * | 2021-05-31 | 2024-01-04 | Shijiazhuang Yiling Pharmaceutical Co., Ltd. | Monoclonal antibodies against cldn18.2 and fc-engineered versions thereof |
| CN118339188A (zh) * | 2021-09-21 | 2024-07-12 | 齐鲁普吉湾生物治疗公司 | 用于制备融合蛋白和双特异性抗体的异二聚体Fc |
| AU2022350588A1 (en) * | 2021-09-27 | 2024-05-02 | Evopoint Biosciences Co., Ltd. | Antibody, antibody-drug conjugate thereof and use thereof |
| WO2023066267A1 (fr) * | 2021-10-19 | 2023-04-27 | Biosion Inc. | Anticorps se liant à cldn18.2 et leurs utilisations |
| CN116102649A (zh) * | 2021-11-11 | 2023-05-12 | 上海生物制品研究所有限责任公司 | 抗cldn18.2单克隆抗体及其应用 |
| WO2024243208A2 (fr) * | 2023-05-22 | 2024-11-28 | Systimmune, Inc. | Anticorps anti-claudine18.2, sa méthode de production et d'utilisation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014075788A1 (fr) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents de traitement de maladies cancéreuses exprimant claudine |
| WO2016165762A1 (fr) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Conjugués de médicaments comprenant des anticorps contre la claudine 18.2 |
| WO2016165765A1 (fr) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1790664A1 (fr) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Anticorps monoclonaux contre claudin-18 pour le traitement du cancer |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| WO2013167153A1 (fr) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Anticorps utiles dans le diagnostic du cancer |
| WO2013174404A1 (fr) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer |
| WO2014127785A1 (fr) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer |
| WO2014146672A1 (fr) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer |
| ES2699753T3 (es) | 2014-01-29 | 2019-02-12 | Biontech Ag | Mimótopos peptídicos de claudina 18.2 y sus usos |
| MA40921A (fr) | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
| CA2874083C (fr) * | 2014-12-05 | 2024-01-02 | Universite Laval | Polypeptides liant le tdp-43 utiles pour le traitement de maladies neurodegeneratives |
| WO2018006882A1 (fr) | 2016-07-08 | 2018-01-11 | 科济生物医药(上海)有限公司 | Anticorps dirigé contre la claudine 18a2 et son utilisation |
| BR112021012608A2 (pt) * | 2018-12-28 | 2021-09-08 | Nanjing GenScript Biotech Co., Ltd. | Porção de ligação que se liga especificamente à claudina18.2, receptor de antígeno quimérico, ácido nucleico, célula imune manipulada, composição farmacêutica, e, método de tratamento de um tumor ou câncer que expressa claudina18.2 |
| US12428478B2 (en) * | 2019-04-01 | 2025-09-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-Claudin 18.2 antibody and application thereof |
-
2020
- 2020-05-15 AU AU2020273695A patent/AU2020273695B2/en active Active
- 2020-05-15 CN CN202080036234.5A patent/CN113825771B/zh active Active
- 2020-05-15 CA CA3138414A patent/CA3138414A1/fr active Pending
- 2020-05-15 KR KR1020217040715A patent/KR20220024010A/ko not_active Ceased
- 2020-05-15 US US17/611,551 patent/US12415853B2/en active Active
- 2020-05-15 JP JP2021568260A patent/JP7407841B2/ja active Active
- 2020-05-15 BR BR112021023024A patent/BR112021023024A2/pt unknown
- 2020-05-15 WO PCT/CN2020/090427 patent/WO2020228806A1/fr not_active Ceased
- 2020-05-15 EP EP20805122.7A patent/EP3971208A4/fr active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014075788A1 (fr) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents de traitement de maladies cancéreuses exprimant claudine |
| WO2016165762A1 (fr) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Conjugués de médicaments comprenant des anticorps contre la claudine 18.2 |
| WO2016165765A1 (fr) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2020228806A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020273695A1 (en) | 2022-01-06 |
| EP3971208A1 (fr) | 2022-03-23 |
| CN113825771B (zh) | 2024-02-09 |
| WO2020228806A1 (fr) | 2020-11-19 |
| US20220411492A1 (en) | 2022-12-29 |
| JP2022533619A (ja) | 2022-07-25 |
| CA3138414A1 (fr) | 2020-11-19 |
| CN113825771A (zh) | 2021-12-21 |
| KR20220024010A (ko) | 2022-03-03 |
| AU2020273695B2 (en) | 2024-10-31 |
| JP7407841B2 (ja) | 2024-01-04 |
| BR112021023024A2 (pt) | 2022-01-25 |
| US12415853B2 (en) | 2025-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3971208A4 (fr) | Anticorps dirigé contre la claudine 18a2 et son utilisation | |
| EP3907240A4 (fr) | Anticorps anti-tnfr2 et son utilisation | |
| EP3904386A4 (fr) | Anticorps et son utilisation | |
| EP3913001C0 (fr) | Anticorps aux chaînes lourdes (vhhs) contre claudin 18a2 et utilisation associée | |
| EP3802612A4 (fr) | Anticorps anti-b7-h3 et son utilisation | |
| EP3889179A4 (fr) | Anticorps bispécifique et son utilisation | |
| EP4141030A4 (fr) | Anticorps anti-cd73 et son utilisation | |
| EP3759143A4 (fr) | Anticorps anti-tigit et leurs utilisations | |
| EP3740224A4 (fr) | Anticorps anti-lilrb et leurs utilisations | |
| EP3898691A4 (fr) | Anticorps trem2 et leurs utilisations | |
| EP3992209A4 (fr) | Anticorps cldn18.2 et son utilisation | |
| EP3978528A4 (fr) | Anticorps anti-récepteur de l'interleukine 4 et son application | |
| EP3880712A4 (fr) | ANTICORPS MONOCLONAUX DIRIGÉS CONTRE LE DOMAINE IgV DE B7-H3 ET SES UTILISATIONS | |
| IL285626A (en) | Claudin 6 antibodies and uses thereof | |
| EP4039708A4 (fr) | Anticorps anti-cll1 et son utilisation | |
| EP4071172A4 (fr) | Anticorps anti-lilrb1 et ses utilisations | |
| EP3735427A4 (fr) | Anticorps anti-mct1 et utilisations associées | |
| EP3725802A4 (fr) | Anticorps anti-synucléine et leurs utilisations | |
| EP4302777A4 (fr) | Anticorps anti-cldn6 et son utilisation | |
| EP4025609A4 (fr) | Anticorps anti-steap1 et leurs utilisations | |
| EP3790586A4 (fr) | Anticorps anti-dll3 et leurs utilisations | |
| EP3962954A4 (fr) | Anticorps anti-galectine-9 et leurs utilisations | |
| EP4001308A4 (fr) | Anticorps anti-tigit et leur application | |
| EP4321535A4 (fr) | Anticorps anti-cntn4 et son utilisation | |
| EP3753955A4 (fr) | Anticorps de protéine cd38 et utilisation associée |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20211210 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20220609BHEP Ipc: A61K 39/395 20060101ALI20220609BHEP Ipc: C12N 5/20 20060101ALI20220609BHEP Ipc: C07K 14/47 20060101ALI20220609BHEP Ipc: C07K 14/725 20060101ALI20220609BHEP Ipc: C07K 16/30 20060101ALI20220609BHEP Ipc: C07K 16/28 20060101AFI20220609BHEP |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20221031 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20221025BHEP Ipc: A61K 39/395 20060101ALI20221025BHEP Ipc: C12N 5/20 20060101ALI20221025BHEP Ipc: C07K 14/47 20060101ALI20221025BHEP Ipc: C07K 14/725 20060101ALI20221025BHEP Ipc: C07K 16/30 20060101ALI20221025BHEP Ipc: C07K 16/28 20060101AFI20221025BHEP |
|
| 17Q | First examination report despatched |
Effective date: 20221111 |